Sanctura XR, a new long-acting formulation of trospium, will soon be another option for treating overactive bladder

January 2008

Sanctura XR, a new long-acting formulation of trospium, will soon be another option for treating overactive bladder.

It'll compete with the other long-acting antimuscarinics...Ditropan XL and Oxytrol (oxybutynin)...Detrol LA (tolterodine)...Vesicare (solifenacin)...and Enablex (darifenacin).

These drugs seem to be similar in efficacy and cost. The big differences are the frequency of side effects and drug interactions.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote